论文部分内容阅读
[目的]评价细胞分裂周期蛋白25B(CDC25B)在乳腺癌中的表达及意义。[方法]2004年1月至2005年12月经病理证实的女性原发性浸润性乳腺癌111例,采用免疫组化方法检测CDC25B表达情况。[结果]CDC25B高表达47例,占42.3%(47/111)。CDC25B高表达组中腋淋巴结阳性26例,占55.3%(26/47);低表达组中腋淋巴结阳性23例,占35.9%(23/64),两组间淋巴结转移率差异有统计学意义(P=0.042)。CDC25B高表达组与低表达组的5年生存率分别为80.9%和92.2%(Log-Rankχ2=4.384,P=0.036)。[结论]乳腺癌组织中CDC25B高表达可能与乳腺癌的发生、发展及转移有关。
[Objective] To evaluate the expression of cyclin 25B (CDC25B) in breast cancer and its significance. [Method] 111 cases of pathologically confirmed female primary invasive breast cancer from January 2004 to December 2005 were studied. The expression of CDC25B was detected by immunohistochemistry. [Results] There were 47 cases with high expression of CDC25B, accounting for 42.3% (47/111). There were 26 positive axillary lymph nodes (55.3%) in CDC25B overexpression group (23/64), 23 cases were axillary lymph node positive in low expression group, the difference was statistically significant (P = 0.042). The 5-year survival rates of CDC25B high expression group and low expression group were 80.9% and 92.2%, respectively (Log-Rankχ2 = 4.384, P = 0.036). [Conclusion] The high expression of CDC25B in breast cancer may be related to the occurrence, development and metastasis of breast cancer.